Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, USA.
Center for Health Services Research, Regenstrief Institute, Indianapolis, IN, USA.
Transl Behav Med. 2023 Sep 12;13(9):710-721. doi: 10.1093/tbm/ibad027.
This pilot study explored the feasibility and acceptability of PARTNER-MH, which aimed to engage racially diverse Veterans in mental health services, facilitate their active participation in care, and improve their communication with providers. Fifty participants were randomized to the intervention or a waitlist control group. For primary outcomes, we assessed the feasibility of the study design and PARTNER-MH's feasibility and acceptability. For secondary outcomes, we explored preliminary effects on patient engagement, patient activation, shared decision-making, and health-related outcomes. The study had a recruitment rate of 68%, enrollment rate of 91%, and a follow-up retention rate of 72%. For intervention feasibility and acceptability, fidelity scores were satisfactory and improved over time, session attendance was modest with 33% of participants completing ≥6 sessions, and 89% of participants were satisfied with the intervention. For secondary outcomes, patients in the intervention arm showed significant improvement on self-reported mental health and depression, compared with those in the control group at both 6- and 9-month follow-ups. However, there were no significant differences between study arms on the other measures. Pilot results provide support for future testing of PARTNER-MH in a larger trial, although modifications are needed to increase session attendance and follow-up retention rate.
The study was preregistered at Clinical Trials.gov. The study Trial registration number is ClinicalTrials.gov NCT04515771.
本研究旨在探索 PARTNER-MH 的可行性和可接受性，以招募不同种族的退伍军人参与心理健康服务，促进他们积极参与治疗，并改善他们与提供者的沟通。将 50 名参与者随机分配到干预组或等待名单对照组。主要结局指标为评估研究设计、PARTNER-MH 的可行性和可接受性。次要结局指标为探索患者参与度、患者激活度、共享决策和健康相关结局的初步影响。该研究的招募率为 68%，入组率为 91%，随访保留率为 72%。对于干预的可行性和可接受性，保真度评分令人满意且随时间推移而提高，参加次数适中，有 33%的参与者完成了≥6 次，89%的参与者对干预表示满意。在次要结局方面，与对照组相比，干预组的患者在 6 个月和 9 个月的随访中，自我报告的心理健康和抑郁情况均有显著改善。然而，两组之间在其他指标上没有显著差异。初步结果为未来更大规模的试验提供了支持，尽管需要进行修改以提高参加次数和随访保留率。
本研究在 ClinicalTrials.gov 上进行了预先注册。研究注册编号为 ClinicalTrials.gov NCT04515771。
